Eli Lilly and Peptron maintain only a non-exclusive research collaboration agreement focused on internal evaluation of the SmartDepot sustained-release microsphere platform for peptide drugs, originally signed in late 2024 with no public extension into commercial rights. Recent reporting through mid-2026 indicates Lilly has validated aspects of the technology yet pursued alternative long-acting delivery partners, such as Camurus, for obesity and related programs. Formal commercial licensing typically requires extensive clinical data, manufacturing scale-up, and regulatory alignment, none of which have been disclosed. With roughly eight weeks remaining until the October 7 resolution date and no announced milestones or executive statements signaling acceleration, trader consensus reflects the low likelihood of completing binding technology transfer or licensing steps in that compressed window.
Eksperymentalne podsumowanie AI odwołujące się do danych Polymarket. To nie jest porada handlowa i nie ma wpływu na rozstrzyganie tego rynku. · ZaktualizowanoEli Lilly licenses Peptron’s SmartDepot by October 7?
Eli Lilly licenses Peptron’s SmartDepot by October 7?
13% szansa
$11,264 Wol.
$11,264 Wol.
Oct 7, 2026
13% szansa
$11,264 Wol.
$11,264 Wol.
Oct 7, 2026
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly and Peptron maintain only a non-exclusive research collaboration agreement focused on internal evaluation of the SmartDepot sustained-release microsphere platform for peptide drugs, originally signed in late 2024 with no public extension into commercial rights. Recent reporting through mid-2026 indicates Lilly has validated aspects of the technology yet pursued alternative long-acting delivery partners, such as Camurus, for obesity and related programs. Formal commercial licensing typically requires extensive clinical data, manufacturing scale-up, and regulatory alignment, none of which have been disclosed. With roughly eight weeks remaining until the October 7 resolution date and no announced milestones or executive statements signaling acceleration, trader consensus reflects the low likelihood of completing binding technology transfer or licensing steps in that compressed window.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Rynek otwarty: May 5, 2026, 8:02 PM ET
Wolumen
$11,264Data zakończenia
Oct 7, 2026Rynek otwarty
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly and Peptron maintain only a non-exclusive research collaboration agreement focused on internal evaluation of the SmartDepot sustained-release microsphere platform for peptide drugs, originally signed in late 2024 with no public extension into commercial rights. Recent reporting through mid-2026 indicates Lilly has validated aspects of the technology yet pursued alternative long-acting delivery partners, such as Camurus, for obesity and related programs. Formal commercial licensing typically requires extensive clinical data, manufacturing scale-up, and regulatory alignment, none of which have been disclosed. With roughly eight weeks remaining until the October 7 resolution date and no announced milestones or executive statements signaling acceleration, trader consensus reflects the low likelihood of completing binding technology transfer or licensing steps in that compressed window.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Wolumen
$11,264Data zakończenia
Oct 7, 2026Rynek otwarty
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...Eli Lilly and Peptron maintain only a non-exclusive research collaboration agreement focused on internal evaluation of the SmartDepot sustained-release microsphere platform for peptide drugs, originally signed in late 2024 with no public extension into commercial rights. Recent reporting through mid-2026 indicates Lilly has validated aspects of the technology yet pursued alternative long-acting delivery partners, such as Camurus, for obesity and related programs. Formal commercial licensing typically requires extensive clinical data, manufacturing scale-up, and regulatory alignment, none of which have been disclosed. With roughly eight weeks remaining until the October 7 resolution date and no announced milestones or executive statements signaling acceleration, trader consensus reflects the low likelihood of completing binding technology transfer or licensing steps in that compressed window.
Eksperymentalne podsumowanie AI odwołujące się do danych Polymarket. To nie jest porada handlowa i nie ma wpływu na rozstrzyganie tego rynku. · Zaktualizowano
Uważaj na linki zewnętrzne.
Uważaj na linki zewnętrzne.
Często zadawane pytania